$EMMA
Emmaus Life Sciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024128621 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $5.478M
YoY Change 9.17%
Cost Of Revenue $394.0K
YoY Change 84.11%
Gross Profit $5.084M
YoY Change 5.83%
Gross Profit Margin 92.81%
Selling, General & Admin $4.117M
YoY Change -5.7%
% of Gross Profit 80.98%
Research & Development $146.0K
YoY Change -64.73%
% of Gross Profit 2.87%
Depreciation & Amortization $5.000K
YoY Change -28.57%
% of Gross Profit 0.1%
Operating Expenses $4.263M
YoY Change -10.82%
Operating Profit $821.0K
YoY Change 3320.83%
Interest Expense $1.338M
YoY Change -29.91%
% of Operating Profit 162.97%
Other Income/Expense, Net
YoY Change
Pretax Income $1.826M
YoY Change 1639.05%
Income Tax -$1.000K
% Of Pretax Income -0.05%
Net Earnings $1.827M
YoY Change 2626.87%
Net Earnings / Revenue 33.35%
Basic Earnings Per Share $0.03
Diluted Earnings Per Share -$0.01
COMMON SHARES
Basic Shares Outstanding 63.87M 63.87M
Diluted Shares Outstanding 162.7M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.255M
Short-Term Investments
Other Short-Term Assets $817.0K
YoY Change 26.28%
Inventory $1.610M
Prepaid Expenses $364.0K
Receivables $4.938M
Other Receivables
Total Short-Term Assets $9.204M
YoY Change -0.57%
LONG-TERM ASSETS
Property, Plant & Equipment $49.00K
YoY Change -18.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $312.0K
YoY Change 6.48%
Total Long-Term Assets $18.14M
YoY Change -52.51%
TOTAL ASSETS
Total Short-Term Assets $9.204M
Total Long-Term Assets $18.14M
Total Assets $27.34M
YoY Change -42.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.489M
YoY Change 35.05%
Accrued Expenses $7.864M
YoY Change -3.67%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $64.13M
YoY Change 5.28%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $13.68M
YoY Change -20.67%
Total Long-Term Liabilities $13.68M
YoY Change -20.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.13M
Total Long-Term Liabilities $13.68M
Total Liabilities $81.12M
YoY Change -3.17%
SHAREHOLDERS EQUITY
Retained Earnings -$260.8M
YoY Change 1.36%
Common Stock $225.9M
YoY Change 1.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$53.78M
YoY Change
Total Liabilities & Shareholders Equity $27.34M
YoY Change -42.38%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $1.827M
YoY Change 2626.87%
Depreciation, Depletion And Amortization $5.000K
YoY Change -28.57%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000822370
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList
http://www.emmausmedical.com/20240930#GainLossOnInvestmentInConvertibleBond
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Other Comprehensive Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2024#OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35527
dei Entity Registrant Name
EntityRegistrantName
EMMAUS LIFE SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0419387
dei Entity Address Address Line1
EntityAddressAddressLine1
21250 Hawthorne Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
Torrance
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90503
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
214-0065
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63865571
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1255000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2547000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4938000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4010000
CY2024Q3 emma Due From Factoring Of Accounts Receivable
DueFromFactoringOfAccountsReceivable
54000
CY2023Q4 emma Due From Factoring Of Accounts Receivable
DueFromFactoringOfAccountsReceivable
1514000
CY2024Q3 us-gaap Inventory Net
InventoryNet
1610000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1711000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1347000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1727000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
9204000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
11509000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1719000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2337000
CY2024Q3 emma Investment In Convertible Bond
InvestmentInConvertibleBond
16059000
CY2023Q4 emma Investment In Convertible Bond
InvestmentInConvertibleBond
20978000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2024Q3 us-gaap Assets
Assets
27343000
CY2023Q4 us-gaap Assets
Assets
35179000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18707000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
16951000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2329000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1639000
CY2024Q3 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
523000
CY2023Q4 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
451000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15650000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14681000
CY2024Q3 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
30000
CY2023Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
65000
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
16205000
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
16383000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
64131000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
61507000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1076000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1839000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13676000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17363000
CY2024Q3 us-gaap Liabilities
Liabilities
81124000
CY2023Q4 us-gaap Liabilities
Liabilities
82935000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63865571
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63865571
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61845963
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5478000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5018000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13361000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22530000
CY2023Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
7733000
emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
3583000
emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
-2000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61845963
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
64000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
62000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
225867000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
225333000
CY2024Q3 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
16869000
CY2023Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
16869000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2016000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-160000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260827000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256122000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-53781000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-47756000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27343000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35179000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5478000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5018000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13361000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22530000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
394000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
214000
us-gaap Cost Of Revenue
CostOfRevenue
892000
us-gaap Cost Of Revenue
CostOfRevenue
1151000
CY2024Q3 us-gaap Gross Profit
GrossProfit
5084000
CY2023Q3 us-gaap Gross Profit
GrossProfit
4804000
us-gaap Gross Profit
GrossProfit
12469000
us-gaap Gross Profit
GrossProfit
21379000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
146000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
414000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
520000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1023000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1318000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1497000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4886000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6345000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2799000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2869000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8400000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11826000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4263000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4780000
us-gaap Operating Expenses
OperatingExpenses
13806000
us-gaap Operating Expenses
OperatingExpenses
19194000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
821000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
24000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1337000
us-gaap Operating Income Loss
OperatingIncomeLoss
2185000
emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
3771000
CY2024Q3 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
7547000
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-647000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-647000
CY2024Q3 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
38000
CY2023Q3 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
589000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
35000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
1034000
CY2024Q3 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
2277000
CY2023Q3 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
3069000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-70000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
2100000
CY2024Q3 emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
0
CY2023Q3 emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
0
emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-544000
emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-297000
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-381000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1347000
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
1032000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-117000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-821000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3227000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
145000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
181000
us-gaap Interest And Other Income
InterestAndOtherIncome
427000
us-gaap Interest And Other Income
InterestAndOtherIncome
514000
CY2024Q3 us-gaap Interest Expense
InterestExpense
1338000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1909000
us-gaap Interest Expense
InterestExpense
4214000
us-gaap Interest Expense
InterestExpense
5204000
CY2024Q3 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
1005000
CY2023Q3 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
81000
emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-3345000
emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-7074000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1826000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
105000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4682000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4889000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1827000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
67000
us-gaap Net Income Loss
NetIncomeLoss
-4705000
us-gaap Net Income Loss
NetIncomeLoss
-4942000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1397000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1614000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2064000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-249000
CY2024Q3 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
0
CY2023Q3 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
0
emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
197000
emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
403000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
225000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
962000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1378000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1389000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1856000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1116000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3205000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1322000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6561000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3826000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63865571
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53637554
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63025296
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52414903
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162726685
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138375065
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63025296
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52414903
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-47756000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
170000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1728000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4348000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-53644000
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
309000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1733000
CY2024Q2 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
197000
CY2022Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5491000
emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
5292000
emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
52000
emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
4595000
CY2023Q3 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
6136000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2184000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-57014000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1397000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1827000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-53781000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
500000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-544000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3451000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-37363000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
CY2023Q2 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
403000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
551000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1558000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-35032000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1614000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
225000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
67000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-36330000
us-gaap Profit Loss
ProfitLoss
-4705000
us-gaap Profit Loss
ProfitLoss
-4942000
us-gaap Depreciation
Depreciation
17000
us-gaap Depreciation
Depreciation
26000
emma Inventory Reserve
InventoryReserve
-14000
emma Inventory Reserve
InventoryReserve
-85000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
632000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1849000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-156000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3167000
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
-544000
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
-297000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1347000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-647000
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
1032000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
emma Gain Loss On Sale Of Loss On Leased Assets
GainLossOnSaleOfLossOnLeasedAssets
-4000
us-gaap Share Based Compensation
ShareBasedCompensation
227000
us-gaap Share Based Compensation
ShareBasedCompensation
1239000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
334000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
35000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
1034000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-70000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
2100000
emma Gain Loss On Option Instrument
GainLossOnOptionInstrument
32000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-536000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4215000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-84000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-636000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-404000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-574000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-66000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1893000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2467000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-4000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
865000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2007000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3238000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2629000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2539000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2508000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2232000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-2647000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2502000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-426000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3201000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5706000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
227000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000
emma Proceeds From Related Party Convertible Debt
ProceedsFromRelatedPartyConvertibleDebt
1000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3684000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5341000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
350000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
110000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
325000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1158000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2482000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-33000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1292000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-516000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2547000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2021000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1255000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1505000
us-gaap Interest Paid Net
InterestPaidNet
1742000
us-gaap Interest Paid Net
InterestPaidNet
1679000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
46000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
35000
emma Renewal Of Notes Payable Including Interests Capitalized
RenewalOfNotesPayableIncludingInterestsCapitalized
618000
emma Conversion Of Convertible Note Payable And Accrued Interest To Common Stock
ConversionOfConvertibleNotePayableAndAccruedInterestToCommonStock
309000
emma Conversion Of Convertible Note Payable And Accrued Interest To Common Stock
ConversionOfConvertibleNotePayableAndAccruedInterestToCommonStock
1500000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
189000
us-gaap Net Income Loss
NetIncomeLoss
-4700000
CY2024Q3 emma Working Capital Deficit
WorkingCapitalDeficit
54900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—Financial statements prepared in accordance with GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include those relating to revenue recognition on product sales, the variables used to calculate the valuation of investment in convertible bond, conversion features, stock options and warrants on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions. To the extent there are material differences between these estimates and actual results, the Company’s financial statements will be affected.</span></p>
emma Number Of Vendors
NumberOfVendors
1
CY2023 emma Number Of Vendors
NumberOfVendors
1
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13760062
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21414769
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
114159810
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
108292553
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reclassification </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">— Certain amounts in the prior period financial statements have been reclassified to confirm to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported loss.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1218000
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1329000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
168000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
186000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5205000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5163000
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4981000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4967000
CY2024Q3 us-gaap Inventory Net
InventoryNet
1610000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1711000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
166000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
595000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
364000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
536000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
817000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
596000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1347000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1727000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
525000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
521000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
476000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
462000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59000
CY2024Q3 us-gaap Depreciation
Depreciation
5000
CY2023Q3 us-gaap Depreciation
Depreciation
7000
us-gaap Depreciation
Depreciation
17000
us-gaap Depreciation
Depreciation
26000
CY2020Q3 us-gaap Debt Instrument Call Date Earliest
DebtInstrumentCallDateEarliest
2020-09-28
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
106000
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-347000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
20978000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
-2508000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-347000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-2064000
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
16059000
CY2024Q3 emma Clinical And Regulatory Expenses
ClinicalAndRegulatoryExpenses
677000
CY2023Q4 emma Clinical And Regulatory Expenses
ClinicalAndRegulatoryExpenses
696000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
975000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
721000
CY2024Q3 emma Accrued Selling Expenses
AccruedSellingExpenses
2477000
CY2023Q4 emma Accrued Selling Expenses
AccruedSellingExpenses
1498000
CY2024Q3 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
837000
CY2023Q4 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
914000
CY2024Q3 emma Accruednonemployeeboardmembercompensation
Accruednonemployeeboardmembercompensation
945000
CY2023Q4 emma Accruednonemployeeboardmembercompensation
Accruednonemployeeboardmembercompensation
766000
CY2024Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
578000
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
518000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6489000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5113000
CY2024Q3 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
823000
CY2023Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
542000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3531000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3122000
CY2024Q3 emma Accrued Payroll Salary And Taxes Current
AccruedPayrollSalaryAndTaxesCurrent
599000
CY2023Q4 emma Accrued Payroll Salary And Taxes Current
AccruedPayrollSalaryAndTaxesCurrent
1270000
CY2024Q3 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
7010000
CY2023Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
5881000
CY2023Q4 emma Accured Due To Customer Current
AccuredDueToCustomerCurrent
844000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
255000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
179000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7864000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8174000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18707000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
16951000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15650000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14681000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13676000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17363000
CY2024Q3 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
29298000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
165000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
29133000
us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
104586425
CY2023Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
30563000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
617000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
29946000
CY2023 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
116906234
CY2024Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.02
CY2024Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.10
CY2024Q3 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.13
CY2023Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.12
CY2024Q3 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.14
CY2023Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.23
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
15375000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11602000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2321000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
29298000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
32000
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
84000
CY2024Q1 emma Fair Value Of Conversion Feature Liability
FairValueOfConversionFeatureLiability
2000
CY2024Q3 emma Fair Value Of Conversion Feature Liability
FairValueOfConversionFeatureLiability
0
CY2022Q3 emma Warrants Granted Term
WarrantsGrantedTerm
P5Y
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.5
CY2023Q3 emma Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
41000
emma Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
45000
CY2023Q1 emma Warrants Granted Term
WarrantsGrantedTerm
P5Y
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.5
us-gaap Share Based Compensation
ShareBasedCompensation
1200000
CY2023Q3 emma Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
459000
emma Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
745000
CY2023Q1 emma Warrant Expired Date
WarrantExpiredDate
2023-11
emma Summary Of Assumptions Used To Value Warrants
SummaryOfAssumptionsUsedToValueWarrants
<p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the assumptions used to value the warrants:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.128%;box-sizing:content-box;"></td> <td style="width:3.441%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:24.105%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:3.441%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.884999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock price</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.47</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.50</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.47</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.50</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term</span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.49</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.03</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.24 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free rate</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.58</span></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">409.38</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411.76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129.40</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130.23</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> </table>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y4M24D
CY2024Q3 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-1000
CY2023Q3 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
38000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
53000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
263000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
291000
us-gaap Operating Lease Expense
OperatingLeaseExpense
853000
us-gaap Operating Lease Expense
OperatingLeaseExpense
878000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1670000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1132000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
846000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3648000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
243000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3405000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1700000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3400000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.129
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-128621-index-headers.html Edgar Link pending
0000950170-24-128621-index.html Edgar Link pending
0000950170-24-128621.txt Edgar Link pending
0000950170-24-128621-xbrl.zip Edgar Link pending
emma-20240930.htm Edgar Link pending
emma-20240930.xsd Edgar Link pending
emma-ex10_1.htm Edgar Link pending
emma-ex31_1.htm Edgar Link pending
emma-ex31_2.htm Edgar Link pending
emma-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img109337448_0.jpg Edgar Link pending
img109337448_1.jpg Edgar Link pending
img109337448_10.jpg Edgar Link pending
img109337448_11.jpg Edgar Link pending
img109337448_12.jpg Edgar Link pending
img109337448_2.jpg Edgar Link pending
img109337448_3.jpg Edgar Link pending
img109337448_4.jpg Edgar Link pending
img109337448_5.jpg Edgar Link pending
img109337448_6.jpg Edgar Link pending
img109337448_7.jpg Edgar Link pending
img109337448_8.jpg Edgar Link pending
img109337448_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
emma-20240930_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable